<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969098</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-02/2009</org_study_id>
    <nct_id>NCT00969098</nct_id>
  </id_info>
  <brief_title>Response Evaluation in Malignant Pleural Mesothelioma</brief_title>
  <official_title>Early Response Evaluation in Malignant Pleural Mesothelioma By Total Glycolytic Volume (TGV) Analysis of Serial FDG-PET Scans (Positron Emission Tomography Scans)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, a few small trials have shown promising results on value of
      fluoro-2-deoxy-D-glucose and positron emission tomography imaging in response assessment in
      Malignant Pleural Mesothelioma. These studies considered different parameters in Positron
      Emission Tomography (PET) analysis, mainly the standardized uptake value and volume-based
      parameters such as total glycolytic volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective analysis of two consecutive and homogeneous series of Malignant
      Pleural Mesothelioma patients treated with first-line pemetrexed-based chemotherapy and
      evaluated by CT scan and FDG-PET.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To validate a semi-automated iterative threshold-based region growing algorithm in a previously published series of patients.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To extend the analysis to another series of consecutive patients with MALIGNANT PLEURAL MESOTHELIOMA treated with first-line pemetrexed-based chemotherapy, and to perform a combined analysis of the two groups.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To validate the new liver-based threshold semi-automated algorithm on the GE ADW4.6 workstation with the algorithm validated in step 1 in the same subset of patients.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically proven MALIGNANT PLEURAL MESOTHELIOMA and Patients not candidate to radical
        surgery
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven MALIGNANT PLEURAL MESOTHELIOMA

          -  Patients not candidate to radical surgery

          -  Unidimensionally and/or bidimensionally CT-measurable disease and Candidate to
             first-line pemetrexed-based chemotherapy

        Exclusion Criteria:

          -  Histologically not proven MALIGNANT PLEURAL MESOTHELIOMA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005 Jul 30-Aug 5;366(9483):397-408. Review.</citation>
    <PMID>16054941</PMID>
  </reference>
  <reference>
    <citation>Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5.</citation>
    <PMID>9869758</PMID>
  </reference>
  <reference>
    <citation>Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44.</citation>
    <PMID>12860938</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8.</citation>
    <PMID>16549838</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Chiti A, Zucali PA, Cappuzzo F, De Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A. Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev. 2007 Oct;33(6):533-41. Epub 2007 Aug 30. Review.</citation>
    <PMID>17764849</PMID>
  </reference>
  <reference>
    <citation>Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004 Feb;15(2):257-60.</citation>
    <PMID>14760119</PMID>
  </reference>
  <reference>
    <citation>Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, Rusch VW. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8.</citation>
    <PMID>17000285</PMID>
  </reference>
  <reference>
    <citation>Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6.</citation>
    <PMID>12878934</PMID>
  </reference>
  <reference>
    <citation>Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005 Jun;46(6):983-95. Review.</citation>
    <PMID>15937310</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006 Oct 1;24(28):4587-93.</citation>
    <PMID>17008700</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histologically proven of Malignant pleural mesothelioma;</keyword>
  <keyword>Patients not candidate to radical surgery;</keyword>
  <keyword>Candidate to first-line pemetrexed-based chemotherapy;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

